Stefan Oschmann, Merck KGaA CEO (Sipa USA via AP Images)
March 1, 2021 07:38 AM ESTUpdated 11:32 AM
Deals
R&D

Mer­ck KGaA ear­marks $855M for De­bio­phar­m's pro­grammed cell death pro­mot­ing drug in glob­al li­cens­ing deal

Kyle Blankenship

Mer­ck KGaA, pri­mar­i­ly known for its CD­MO work, is play­ing with gi­ants in on­col­o­gy and look­ing at nov­el mech­a­nisms of ac­tion to com­pete. Now, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times